Dashboard/BMY/CAMZYOS/event

ReadoutTopline Readout

CAMZYOS ODYSSEY-HCM Phase 3 Topline (nHCM)

BMY·CAMZYOS·Hypertrophic Cardiomyopathy·

Approved

·NCT04349072

current best date

'27

QTR11 months

Takeaway

Phase 3 efficacy readout for CAMZYOS in non-obstructive HCM. CAMZYOS is currently approved only in the obstructive form (oHCM); non-obstructive HCM has roughly 2x the U.S. patient population. Watch: KCCQ-23 score and pVO2 change vs. placebo.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~100%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAcardiac myosin inhibitor

CAMZYOS (mavacamten) is a first-in-class oral cardiac myosin inhibitor developed by Bristol Myers Squibb that treats hypertrophic cardiomyopathy (HCM) — a genetic condition in which the heart muscle thickens abnormally and obstructs blood flow. The drug reduces the number of myosin-actin cross-bridges that form during each heartbeat, decreasing the force of contraction and relieving the outflow obstruction that causes breathlessness, chest pain, and syncope. CAMZYOS is approved for symptomatic obstructive HCM and is being studied in non-obstructive HCM — a distinct phenotype with twice the patient population and no approved drug therapy — in an ongoing Phase 3 trial.

Indication

Cardiology - HFpEF

Hypertrophic Cardiomyopathy

MeSH · D002311

No primer in glossary yet.

Trial

active

NCT04349072 ↗

ODYSSEY-HCM Phase 3 Mavacamten in nHCM

Reference data · comparable readouts

How Appr readouts in Cardiology - HFpEF have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

0/0

0% in record

Primary endpoint hit

across 0 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

aficamten (SEQUOIA-HCM)

CYTK · HCM

Ph3 · Dec 2024positivepVO2 +1.8 mL/kg/minPR

mavacamten (EXPLORER-HCM)

BMY · HCM

Ph3 · May 2020positivepVO2 +1.4 mL/kg/min vs +0.1 pboPR

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Prior BMY reactions to Readout events

1 historical event · base rate, not prediction

Median 1W move

-35.7%

Median 1M move

-19.8%

Positive outcomes

0/ 1

Negative outcomes

1/ 1

100%

Date	Headline	Outcome	1W	1M	6M
Jul 2024	CAMZYOS — Phase 3 Topline — Mixed Result	negative	-35.7%	-19.8%	-29.2%

Historical BMY stock reaction to past Readout catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 0%.

Disclosure trail

1 observation · sorted by confidence

Apr 22, 2026·8d agopinned · highest confidence
MED confPR
top claim
Q2'27
QTR
“Topline results from ODYSSEY-HCM are anticipated in the second quarter of 2027.”
conf 83%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.